Compare Cassava Sciences Inc (FLNA) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs OneSpan Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while OneSpan Inc trades at $15.6 (market cap $571.66M). The key difference: OneSpan Inc is far larger — about 10.8× Cassava Sciences Inc's market cap, and OneSpan Inc pays a 3.37% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | OSPN | |
|---|---|---|
Market Cap | $53.14M | $571.66M |
Sector | Health | Technology |
52-Week High | $4.64 | $16.32 |
52-Week Low | $1.09 | $10.15 |
Enterprise Value | -$33.43M | $529.87M |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
OSPN trades at $15.70, up 1.36% today, with a bullish technical signal from moving averages and strong profitability metrics including a 28.47% net income margin and 27.81% ROE. Recent earnings beats and a scheduled Q2 2026 report on August 4, 2026, highlight operational momentum, while a dividend payment in June 2026 adds shareholder return.
The stock presents a value opportunity with a P/E of 8.52, supported by analyst consensus of Buy (66.7%) and a $13.50 price target. Risks include negative net cash flow trends and competitive pressures in cybersecurity, but earnings consistency and institutional optimism suggest upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
